Page last updated: 2024-12-05

4-methylbenzyl alcohol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-methylbenzyl alcohol: a pulmonary metabolite of para-xylene [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-methylbenzyl alcohol : A methylbenzyl alcohol in which the methyl substituent is para to the hydroxymethyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11505
CHEMBL ID90100
CHEBI ID1895
SCHEMBL ID3337
MeSH IDM0205623

Synonyms (80)

Synonym
AC-13074
CHEMBL90100
p-tolyl-methanol
benzenemethanol, 4-methyl-
p-tolylcarbinol
p-methylbenzyl alcohol
nsc3992
4-(hydroxymethyl)toluene
benzyl alcohol, p-methyl-
nsc-3992
p-toluyl alcohol
4-methyl benzenemethanol
4-methylbenzenemethanol
CHEBI:1895 ,
inchi=1/c8h10o/c1-7-2-4-8(6-9)5-3-7/h2-5,9h,6h2,1h
(4-methylphenyl)methanol
p-methyl benzyl alcohol
NCGC00091215-01
ai3-09610
4-methyl-benzenemethanol
p-methylbenzylalcohol
nsc 3992
ccris 5112
p-methylbenzylalkohol [german]
einecs 209-639-1
brn 1856550
4-tolylcarbinol
alpha-hydroxy-p-xylene
589-18-4
4-methylbenzyl alcohol
C06757
4-methylbenzyl alcohol, 98%
AKOS000249530
4-methyl-benzenemethanol (9ci)
BMSE000520
M0162
p-tolylmethanol;4-methylbenzyl alcohol
A832074
NCGC00091215-02
NCGC00257643-01
dtxsid5025574 ,
tox21_200089
dtxcid205574
cas-589-18-4
31831-37-5
xylene-alpha-ol
ar-methylbenzenemethanol
hsdb 7615
p-methylbenzylalkohol
4-06-00-03171 (beilstein handbook reference)
unii-exz915a627
exz915a627 ,
FT-0619068
FT-0619071
p-tolylmethanol
(4-tolyl)methanol
p-tolualcohol
fema no. 4624
4-methylbenzyl alcohol [hsdb]
methyl benzyl alcohol, p-
p-toluic alcohol
SCHEMBL3337
4-methyl-benzylalcohol
4-methylbenzylalcohol
(4-methylphenyl)-methanol
W-105355
4-methylbenzenemethanol, 9ci
1-hydroxymethyl-4-methylbenzene
a-hydroxy-p-xylene
4-methyl-1-hydroxymethylbenzene
(4-methylphenyl)methanol #
mfcd00004664
VTG ,
CS-W016577
4-methyl benzyl alcohol
Q27067434
AMY21965
D77794
4-methyl-benzyl alcohol
EN300-49120
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
xenobiotic metaboliteAny metabolite produced by metabolism of a xenobiotic compound.
fragranceA substance, extract, or preparation for diffusing or imparting an agreeable or attractive smell.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
methylbenzyl alcoholMembers of the class of benzyl alcohols substituted by at least one methyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
1,4-dimethylbenzene degradation to 4-methylbenzoate39
p-xylene degradation to p-toluate26

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency69.42750.006038.004119,952.5996AID1159521
AR proteinHomo sapiens (human)Potency28.82420.000221.22318,912.5098AID1259243; AID1259381; AID588516
progesterone receptorHomo sapiens (human)Potency17.43940.000417.946075.1148AID1346784
retinoid X nuclear receptor alphaHomo sapiens (human)Potency0.19730.000817.505159.3239AID1159527
estrogen nuclear receptor alphaHomo sapiens (human)Potency34.79620.000229.305416,493.5996AID1259244
activating transcription factor 6Homo sapiens (human)Potency0.04960.143427.612159.8106AID1159516
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency74.97800.000627.21521,122.0200AID651741
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency34.79620.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency34.79620.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sulfotransferase 1A1 Rattus norvegicus (Norway rat)Km600.00005.00007.571410.0000AID39219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID87806Antibacterial activity against Helicobacter pylori ATCC 43504 was determined2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
A specific anti-Helicobacter pylori agent NE2001: synthesis and its effect on the growth of H. pylori.
AID13312991-octanol/D2O distribution coefficient, log D of the compound at pH 7.4 by 1H NMR spectroscopic analysis
AID207179Antibacterial activity against Staphylococcus aureus 209P JC was determined2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
A specific anti-Helicobacter pylori agent NE2001: synthesis and its effect on the growth of H. pylori.
AID39220Maximal velocity (Vmax) against Arylsulfotransferase (AST IV)2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Comparative molecular field analysis of substrates for an aryl sulfotransferase based on catalytic mechanism and protein homology modeling.
AID1331301n-Octanol/water partition coefficient, log P of the compound by HPLC method
AID39219Apparent Michaelis constant (Km) against Arylsulfotransferase (AST IV)2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Comparative molecular field analysis of substrates for an aryl sulfotransferase based on catalytic mechanism and protein homology modeling.
AID229377Ratio of kcat/Km determined for catalytic efficiency in sulfonation against AST IV2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Comparative molecular field analysis of substrates for an aryl sulfotransferase based on catalytic mechanism and protein homology modeling.
AID1331300Lipophilicity, log D of the compound at pH 7.4 by HPLC method
AID69916Antibacterial activity against Escherichia coli K-12 was determined2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
A specific anti-Helicobacter pylori agent NE2001: synthesis and its effect on the growth of H. pylori.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's3 (42.86)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.82 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index47.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]